Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Haemophilia. 2019 Sep;25(5):755-763. doi: 10.1111/hae.13777. Epub 2019 Jul 11.
Although the clinical manifestations of severe haemophilia A (HA) are well studied, the challenges, if any, of living with mild HA are not clearly delineated to date.
To assess available evidence of clinical risks and societal/economic impacts of disease in adult patients with mild HA using a systematic literature review.
Prespecified study selection criteria were applied in a comprehensive literature search. Included studies varied in design and reported outcomes of interest for adults (≥13 years of age) with mild HA.
Seventeen studies with a total of 3213 patients met eligibility criteria (published or presented in English, 1966-2017). Most studies were observational, and the outcomes reported were too sparse and dissimilar to support a formal meta-analysis. Mean annual bleeding rates ranged from 0.44 to 4.5 episodes per patient per year. Quality of life (QoL; SF-36 General Health) was impacted compared to healthy controls. Health care costs and productivity were seldom assessed and no robust comparisons to healthy controls were available.
Quantifying outcomes for adult patients with mild HA remains challenging, with estimates of key QoL and cost data often based on small data sets and without comparison to population norms. Therefore, the clinical impact of mild haemophilia may be under-represented and unmet needs may remain unaddressed. As paradigm-changing therapies for HA emerge, stronger knowledge of mild HA can guide the development of care options that minimize burden and enhance the QoL for this segment of the haemophilia community, and for the haemophilia community in totality.
尽管重度甲型血友病(HA)的临床表现已有深入研究,但目前仍不清楚轻度 HA 患者的生活所面临的挑战。
使用系统文献回顾评估轻度 HA 成年患者的疾病临床风险和社会/经济影响的现有证据。
在全面文献检索中应用了预先规定的研究选择标准。纳入的研究在设计上存在差异,并报告了对轻度 HA 成年患者(≥13 岁)感兴趣的结局。
符合入选标准的共有 17 项研究,共纳入 3213 例患者(发表或呈现在英文文献中,时间为 1966-2017 年)。大多数研究为观察性研究,报告的结局过于稀疏且各不相同,无法支持正式的荟萃分析。平均每年出血率为 0.44 至 4.5 次/患者/年。与健康对照组相比,生活质量(SF-36 一般健康状况)受到影响。很少评估医疗保健费用和生产力,且无法与健康对照组进行稳健比较。
量化轻度 HA 成年患者的结局仍然具有挑战性,关键的生活质量和成本数据估计通常基于小数据集,且没有与人群正常值进行比较。因此,轻度血友病的临床影响可能被低估,未满足的需求可能仍未得到解决。随着 HA 的变革性治疗方法的出现,对轻度 HA 的深入了解可以指导制定护理方案,减轻这一血友病患者群体的负担,提高他们的生活质量,同时也可以提高整个血友病患者群体的生活质量。